- Home
- JGH vs NNNN Comparison
JGH vs NNNN Comparison
Compare JGH & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- NNNN
- Stock Information
- Founded
- JGH 2014
- NNNN 2021
- Country
- JGH United States
- NNNN Germany
- Employees
- JGH N/A
- NNNN N/A
- Industry
- JGH Investment Managers
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JGH Finance
- NNNN Health Care
- Exchange
- JGH Nasdaq
- NNNN Nasdaq
- Market Cap
- JGH 285.5M
- NNNN 267.7M
- IPO Year
- JGH N/A
- NNNN 2025
- Fundamental
- Price
- JGH $12.64
- NNNN $6.79
- Analyst Decision
- JGH
- NNNN
- Analyst Count
- JGH 0
- NNNN 0
- Target Price
- JGH N/A
- NNNN N/A
- AVG Volume (30 Days)
- JGH 73.9K
- NNNN 29.7K
- Earning Date
- JGH 01-01-0001
- NNNN 01-01-0001
- Dividend Yield
- JGH 9.85%
- NNNN N/A
- EPS Growth
- JGH N/A
- NNNN N/A
- EPS
- JGH N/A
- NNNN 0.06
- Revenue
- JGH N/A
- NNNN $8,185,146.00
- Revenue This Year
- JGH N/A
- NNNN N/A
- Revenue Next Year
- JGH N/A
- NNNN N/A
- P/E Ratio
- JGH N/A
- NNNN $114.60
- Revenue Growth
- JGH N/A
- NNNN 21.95
- 52 Week Low
- JGH $10.36
- NNNN $5.18
- 52 Week High
- JGH $12.85
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- JGH 61.49
- NNNN N/A
- Support Level
- JGH $12.35
- NNNN N/A
- Resistance Level
- JGH $12.47
- NNNN N/A
- Average True Range (ATR)
- JGH 0.14
- NNNN 0.00
- MACD
- JGH 0.07
- NNNN 0.00
- Stochastic Oscillator
- JGH 93.43
- NNNN 0.00
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.